Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04033094 · ClinicalTrials.gov registry record
Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)
A clinical trial, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 17,566
- Enrollment target
NCT04033094 is a clinical trial that has completed, run by Daiichi Sankyo. The registered enrollment target is 17,566 participants.
The verdict
NCT04033094 has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 17,566 participants
- Enrollment target
Study Summary
The main objectives of this study are to provide surveillance/descriptive data to (a) assess utilization of MorphaBond ER and selected comparators overall and by age group and census regions using nationally-projected quarterly drug dispensing data and (b) assess the scope and pattern of abuse and clinical outcomes for MorphaBond ER using nationally representative data or data from large geographic areas in different populations. Findings of this study will support the design of formal epidemiology assessment of the risks of addiction, overdose, and death outcomes associated with MorphaBond ER and appropriate comparators in the future.
Interventions
- DRUG Comparator Drug
- DRUG MorphaBond ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,566 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2020-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04033094
The ClinicalTrials.gov registry entry for NCT04033094 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 17,566 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Comparator Drug is the first listed.
NCT04033094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04033094 about?
NCT04033094 is a clinical study titled "Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)". The main objectives of this study are to provide surveillance/descriptive data to (a) assess utilization of MorphaBond ER and selected comparators overall and by age group and census regions using nationally-projected quarterly drug dispensing data and (b) assess the scope and pattern of abuse and c...
What is the current status of trial NCT04033094?
This trial is currently completed. The enrollment target is 17,566 participants. The study started on 2017-10-16. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT04033094?
The interventions under investigation include: Comparator Drug (DRUG), MorphaBond ER (DRUG).
Who is sponsoring clinical trial NCT04033094?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.